NEUROBIOGEN has been working with an advisory network of researchers and clinical
experts specializing in brain & neurological diseases with long experience.
Mission & Vision
Innovative new medicine R&D company treating degenerative brain diseases and central nervous system diseases
KDS2010 (SeReMABI) is a reversible inhibitor derived from a new treatment mechanism for Alzheimer's, and we're developing a new drug based on the mechanism of KDS2010 that improves cognitive function by acting on reactive astrocytes.
Global bio-company at home and abroad
Our vision is to grow into a global leading company that is respected worldwide, not just in Korea.
Innovative company, the bridgehead for conquering human diseases and moving toward a better future
Our vision is to play a key role in finding a way to the future in which incurable diseases that at present mankind has not overcome can finally be cured.